Stifel Nicolaus Begins Coverage on Insulet (NASDAQ:PODD)

Investment analysts at Stifel Nicolaus initiated coverage on shares of Insulet (NASDAQ:PODD) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $370.00 price target on the medical instruments supplier’s stock. Stifel Nicolaus’ price target suggests a potential upside of 12.39% from the company’s current price.

PODD has been the topic of a number of other research reports. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a research note on Thursday, August 7th. Wells Fargo & Company lifted their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Zacks Research upgraded shares of Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Leerink Partners raised their price target on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research report on Tuesday, October 14th. Finally, Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $352.11.

Insulet Stock Performance

Shares of PODD opened at $329.22 on Tuesday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $23.17 billion, a P/E ratio of 100.07, a P/E/G ratio of 2.75 and a beta of 1.40. The business’s 50 day moving average price is $327.45 and its 200-day moving average price is $303.46. Insulet has a 52 week low of $226.50 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter last year, the company earned $0.55 EPS. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently made changes to their positions in PODD. Larson Financial Group LLC boosted its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Insulet during the 1st quarter worth $26,000. SouthState Corp boosted its stake in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares during the last quarter. True Wealth Design LLC grew its position in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the period. Finally, Kozak & Associates Inc. purchased a new stake in shares of Insulet in the 2nd quarter worth $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.